Jun 01, 2020
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
May 26, 2020
CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
May 21, 2020
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin
Apr 29, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
Feb 28, 2020
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
Feb 28, 2020
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
Feb 11, 2020
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
Feb 04, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
Dec 19, 2019
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
Jul 30, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
Jul 22, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
Jun 26, 2019
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
May 02, 2019
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
Apr 29, 2019
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
Sep 13, 2018
CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S